Table II.
The association of MCM2 and TIP30 expression with the clinicopathological characteristics of SC/ASC.
| MCM2 | TIP30 | ||||||
|---|---|---|---|---|---|---|---|
| Clinicalpathological characteristics | Total no. | Pos no. (%) | χ2 | P-value | Pos no. (%) | χ2 | P-value |
| Sex | 0.090 | 0.765 | 1.565 | 0.211 | |||
| Male | 19 | 9 (47.4) | 12 (63.2) | ||||
| Female | 27 | 14 (51.9) | 12 (44.6) | ||||
| Age (years) | 0.357 | 0.550 | 0.270 | 0.603 | |||
| ≤45 | 3 | 1 (33.3) | 2 (66.7) | ||||
| >45 | 43 | 22 (51.2) | 22 (51.2) | ||||
| Pathological type | 0.354 | 0.552 | 2.333 | 0.127 | |||
| SC | 26 | 14 (53.8) | 11 (42.3) | ||||
| ASC | 20 | 9 (45.0) | 13 (65.0) | ||||
| Differentiation | 7.167 | 0.028 | 3.753 | 0.153 | |||
| Well | 16 | 6 (37.5) | 10 (62.5) | ||||
| Moderately | 24 | 11 (45.8) | 13 (54.2) | ||||
| Poorly | 6 | 6 (100.0) | 1 (16.7) | ||||
| Tumor mass size | 5.662 | 0.017 | 7.389 | 0.007 | |||
| ≤3 cm | 20 | 6 (30.0) | 15 (75.0) | ||||
| >3 cm | 26 | 167 (65.4) | 9 (34.6) | ||||
| Gallstones | 0.365 | 0.546 | 0.708 | 0.400 | |||
| No | 18 | 10 (55.6) | 8 (44.4) | ||||
| Yes | 28 | 13 (46.4) | 16 (57.1) | ||||
| TNM stage | 10.943 | 0.004 | 9.936 | 0.008 | |||
| I+II | 12 | 3 (25.0) | 10 (83.3) | ||||
| III | 20 | 8 (40.0) | 11 (55.0) | ||||
| IV | 14 | 12 (85.7) | 3 (21.4) | ||||
| Lymph metastasis | 4.572 | 0.032 | 6.379 | 0.012 | |||
| No | 17 | 5 (29.4) | 13 (76.5) | ||||
| Yes | 29 | 18 (62.1) | 11 (37.9) | ||||
| Invasion | 6.133 | 0.013 | 12.270 | 0.000 | |||
| No | 16 | 4 (25.0) | 14 (87.5) | ||||
| Yes | 30 | 19 (63.3) | 10 (33.3) | ||||
| Surgery | 7.365 | 0.025 | 9.296 | 0.00 | |||
| Radical | 14 | 3 (21.4) | 11 (78.6) | ||||
| Palliative | 18 | 10 (55.6) | 10 (55.6) | ||||
| Biopsy | 14 | 10 (71.4) | 3 (21.4) | ||||
MCM2, minichromosome maintenance complex component 2; TIP30, HIV-1 tat interactive protein 2; SC, squamous cell; ASC, adenosquamous carcinoma.